Adjuvanted coronavirus vaccine - Dynavax Technologies/Medicago
Alternative Names: Adjuvanted coronavirus recombinant vaccine - Dynavax Technologies/Medicago; Coronavirus-Like Particle COVID-19 Vaccine adjuvanted; CoVLP vaccine; Recombinant Coronavirus Virus-Like Particle vaccine - Dynavax Technologies/MedicagoLatest Information Update: 28 Aug 2023
At a glance
- Originator Dynavax Technologies; Medicago
- Developer Medicago
- Class COVID-19 vaccines; Synthetic vaccines; Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in Canada (IM)
- 22 Apr 2022 Medicago completes a phase I trial in COVID-2019 infection (Prevention) in Canada (NCT04450004)
- 10 Nov 2020 Immunogenicity and safety data from a phase I trial for COVID-2019 infections released by Medicago